✦ LIBER ✦

Long Term Outcomes for Alemtuzumab Based Reduced Intensity Conditioning Transplant for Myelodysplastic Syndromes and Acute Myeloid Leukaemia

✍ Scribed by V.T. Potter; P. Krishnamurthy; V.J. Tindell; Z. Lim; R. Ireland; J.C. Marsh; A. Pagliuca; M.J. Ghulam

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Term Outcomes of Alemtuzumab-Based

✍ Potter, Victoria T.; Krishnamurthy, Pramila; Barber, Linda D.; Lim, ZiYi; Kenyon 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 595 KB

Outcomes of alemtuzumab-based reduced in

✍ Zi Yi Lim; Aloysius Y. L. Ho; Wendy Ingram; Michelle Kenyon; Laurence Pearce; Ba 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 572 KB

Delayed attainment of full donor chimaer

✍ Zi Yi Lim; Laurence Pearce; Aloysius Y. Ho; Linda Barber; Wendy Ingram; Monica U 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Outcomes following 50 mg versus 100 mg a

✍ Eleni Tholouli; Effie Liakopoulou; Hayley M. Greenfield; Bronwen E. Shaw; Sudhir 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Reduced-intensity allogeneic hematopoiet

✍ Ho, A. Y. L. 📂 Article 📅 2004 🏛 American Society of Hematology 🌐 English ⚖ 90 KB

Alemtuzumab vs ATG for T-Cell Depletion

✍ V.T. Potter; V.J. Tindell; L. Reiff-Zall; A. Ho; M. Kenyon; J. Marsh; A. Pagliuc 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB